On the contrary, a follow up high-throughput screen of venetoclax in ∼800 solid tumor cancer cell lines demonstrated that only two groups of solid tumor cancers were sensitive: a subset of MYCN-amplified neuroblastomas [5], and a subset of high BCL-2 expressing SCLCs [1]. This evidence concerns the gene BCL2 and neuroblastoma.